News
Filter by:

CytoSen Therapeutics Appoints Experienced Financial Executive, Jason Wilson, to Its Board of Directors

October 8, 2018

Dallas, TX – October 8, 2018 – CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer (NK) cell therapy™, today announced the appointment of Jason…

Learn More

CytoSen Therapeutics and KBI Biopharma Enter Into Strategic Partnership to Manufacture NK Cells and Nanoparticles

October 2, 2018

Implementing scalable manufacturing processes to enable cGMP production of investigational Natural Killer cell therapies Dallas, TX and Durham, NC – October 2, 2018 – CytoSen Therapeutics and…

Learn More

CytoSen Therapeutics receives FDA’s favorable response to pre-IND Meeting Package for Phase 2 study in AML

September 27, 2018

Dallas, TX – September 26, 2018 – CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer (NK) cell therapy™, today announced it has received a…

Learn More

CytoSen Therapeutics Appoints Scientific Advisory Board

October 23, 2017

CytoSen Therapeutics announced today the appointment of five new members to the company’s scientific and medical advisory board. Drs. Michael Caligiuri, Zhijian “James” Chen, Todd Fehniger, Helen Heslop, and Jeffrey Miller will join Drs. Dean Lee and Stefan Ciurea on the board as medical and scientific advisors.

Learn More

Researchers show feasibility of ex vivo expanded NK cell therapy for acute myeloid leukemia

September 14, 2017

Researchers published data last month showing the feasibility and safety for preventing relapse of acute myeloid leukemia (AML) by treating with ex vivo expanded NK cells in combination with haploindentical hematopoietic stem cell transplantation (HSCT).

Learn More